Company Encyclopedia
View More
name
Icecure Medical
ICCM.US
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
1.391 T
ICCM.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking131/174
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-157.91%E
    • Profit Margin-513.95%E
    • Gross Margin32.59%C
  • Growth ScoreD
    • Revenue YoY-18.96%E
    • Net Profit YoY-10.52%D
    • Total Assets YoY-1.31%D
    • Net Assets YoY-7.50%D
  • Cash ScoreD
    • Cash Flow Margin-19.46%D
    • OCF YoY-18.96%E
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreB
    • Gearing Ratio38.28%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    IceCure Medical showcases FDA-cleared ProSense cryoablation system for minimally invasive breast cancer treatment

    IceCure Medical Ltd. has highlighted its FDA-cleared ProSense® cryoablation system for minimally invasive treatment of early-stage low-risk breast cancer in women aged 70 and above. The system, using liquid nitrogen-based technology, offers an alternative to traditional surgery and is also approved for other applications. The company has regulatory approvals in 15 countries, global distribution agreements, and received the 2024 Scientific Impact Award. IceCure holds over 54 patents related to its technology.

    Reuters·
    US
    ICCM
    -1.35%
    Reuters·
    US
    ICCM
    -1.35%

    IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer | ICCM Stock News

    IceCure Medical Ltd. anticipates record fourth quarter sales in North America, driven by FDA clearance of its ProSense® Cryoablation system for low-risk breast cancer. The system, which offers a minimally invasive alternative to surgery, is gaining traction among medical institutions. The FDA's approval has spurred interest and orders from top hospitals, enhancing the company's sales pipeline. IceCure plans to release preliminary revenue results in January 2026, with a full report in April 2026.

    StockTitan·
    US
    ICCM
    -1.35%
    StockTitan·
    US
    ICCM
    -1.35%

    IceCure's ProSense® Cryoablation featured in 4 breast cancer studies with 263 patients presented at RSNA 2025.

    During a conference in CAESAREA, Israel on December 10, 2025, abstracts of 3 studies were presented involving a total of 263 patients. These studies contribute to the increasing evidence base supporting the wider use of ProSense®. IceCure Medical Ltd. (NASDAQ: ICCM) shared this information, highlighting the positive results across diverse patient populations.

    Unusual Whales·
    US
    ICCM
    -1.35%
    Unusual Whales·
    US
    ICCM
    -1.35%

    IceCure Medical Showcases ProSense Cryoablation Data at RSNA 2025 Annual Meeting

    IceCure Medical showcased its ProSense cryoablation technology for breast cancer treatment at the RSNA 2025 Annual Meeting in Chicago. Four independent studies highlighted the effectiveness and adoption of this minimally-invasive system as an alternative to surgical tumor removal. The event attracted 50,000 attendees from 160 countries, emphasizing advancements in radiology and cancer care.

    Reuters·
    US
    ICCM
    -1.35%
    Reuters·
    US
    ICCM
    -1.35%

    SEGG Media Congratulates Lando Norris on 2025 Formula 1 World Championship | SEGG Stock News

    IceCure Medical showcased its ProSense® cryoablation technology at the CIRSE Annual Meeting, highlighting its effectiveness in treating breast cancer and endometriosis. The event featured presentations and studies demonstrating ProSense® as a promising non-surgical treatment option, especially for elderly patients and those ineligible for surgery. The technology is gaining interest among interventional radiologists for expanding breast cancer care.

    StockTitan·
    US
    ICCM
    -1.35%
    StockTitan·
    US
    ICCM
    -1.35%
    © 2025 Longbridge｜Disclaimer